Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenotonsillectomy Clear all
Completed No phase listed Observational

Surgical Treatment of Children With OSA and Small Tonsils or Down Syndrome

NCT05154214
View directory record Official record
Conditions
Obstructive Sleep Apnea of Child
Interventions
Adenotonsillectomy, Drug-induced sleep endoscopy directed surgery
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 24, 2026, 5:10 PM EDT
Recruiting No phase listed Observational

Postoperative Pain After Pediatric Adenotonsillectomy With Ketorolac or Ibuprofen

NCT07672418
View directory record Official record
Conditions
Sleep, Pediatrics, Adenotonsillectomy
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dexmedetomidine in Pediatric Tonsillectomy

NCT01057381
View directory record Official record
Conditions
Pediatric Adenotonsillectomy, Post Operative Analgesia
Interventions
Dexmedetomidine 0.75 mcg/kg, Morphine 50 mcg/kg, Morphine 100 mcg/kg, Dexmedetomidine 1 mcg/kg
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 24, 2026, 5:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

NCT07293754
View directory record Official record
Conditions
Advanced Malignant Solid Tumor
Interventions
RPTR-1-201, PD-1 / PD-L1 monoclonal antibody
Drug
Lead sponsor
Repertoire Immune Medicines
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy

NCT03625011
View directory record Official record
Conditions
Tonsillitis, Tonsillectomy
Interventions
Gabapentin
Drug
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
3 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

NCT05441501
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-80038114
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 24, 2026, 5:10 PM EDT
Recruiting Phase 1 Interventional

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

NCT05887167
View directory record Official record
Conditions
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma
Interventions
autologous hematopoietic stem cells added to planned CAR T
Biological
Lead sponsor
Joshua Sasine, MD, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Recruiting Phase 1 Interventional

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

NCT07319871
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pasritamig, JNJ-86974680
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Sarasota, Florida • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Completed No phase listed Observational

Pharmacogenomics Analysis of Morphine Pharmacokinetics in Pediatric Tonsillectomy and Adenoidectomy

NCT00836264
View directory record Official record
Conditions
Tonsillectomy, Adenoidectomy, Pharmacokinetics
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 18 Years
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 24, 2026, 5:10 PM EDT
Active, not recruiting Phase 1 Interventional

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

NCT05184569
View directory record Official record
Conditions
Semantic Dementia
Interventions
Verdiperstat
Drug
Lead sponsor
Peter Ljubenkov, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

NCT00357396
View directory record Official record
Conditions
Sarcoma
Interventions
graft versus host disease prophylaxis/therapy, busulfan, melphalan, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

NCT03247309
View directory record Official record
Conditions
Solid Tumor, Cancer, Recurrent Solid Tumors, Refractory Solid Tumors
Interventions
IMA201 Product, IMADetect®
Biological · Diagnostic Test
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 24, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).

NCT00273754
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Tonsillectomy, Adenoidectomy, Postoperative Complications
Interventions
Caffeine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Months to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 24, 2026, 5:10 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

NCT07082920
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343, JNJ-95298177, JNJ-87189401
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Sarasota, Florida • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Completed No phase listed Observational

Bradycardia Following Intraoperative Administration of Dexmedetomidine

NCT01917097
View directory record Official record
Conditions
Tonsillectomy, Adenotonsillectomy
Interventions
Dexmedetomidine
Drug
Lead sponsor
Joseph D. Tobias
Other
Eligibility
Not listed
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 24, 2026, 5:10 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-opioids for Analgesia After Adenotonsillectomy in Children

NCT03618823
View directory record Official record
Conditions
Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions
Oxycodone, Ibuprofen, Acetaminophen
Drug
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

Safety Study of Quickclot for Bleeding Control After Adenotonsillectomy

NCT01863563
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
QuickClot
Device
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 24, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

NCT03759678
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
IB1001
Drug
Lead sponsor
IntraBio Inc
Industry
Eligibility
6 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab in T1DM

NCT05574335
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Siplizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Aurora, Colorado • Iowa City, Iowa • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 24, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

NCT01010217
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
Interventions
Cyclophosphamide, Fludarabine, Melphalan, Mesna, Rituximab, Stem Cell Transplantation, Thiotepa, Tacrolimus, Mycofenolate mofetil, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 24, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ketorolac on Postoperative Pain Reduction in Pediatric Patients with Adenotonsillectomy

NCT05074056
View directory record Official record
Conditions
Adenotonsillar Hypertrophy, Obstructive Sleep Apnea, Sleep-Disordered Breathing, Acute Post Operative Pain
Interventions
Ketorolac
Drug
Lead sponsor
St. Louis University
Other
Eligibility
3 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 24, 2026, 5:10 PM EDT
Active, not recruiting Phase 3 Interventional

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

NCT06673056
View directory record Official record
Conditions
Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
Interventions
N-Acetyl-L-Leucine, Placebo
Drug · Other
Lead sponsor
IntraBio Inc
Industry
Eligibility
4 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 24, 2026, 5:10 PM EDT
Terminated Phase 4 Interventional Results available

The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation

NCT02162433
View directory record Official record
Conditions
Adenotonsillar Hypertrophy, Obstructive Sleep Apnea, Tonsillitis, Adenoiditis
Interventions
Normal Saline, Dexmedetomidine
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
3 Years to 16 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 24, 2026, 5:10 PM EDT